Zacks: Analysts Expect Momenta Pharmaceuticals, Inc. (MNTA) to Post -$0.45 EPS

Equities research analysts expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to post earnings of ($0.45) per share for the current quarter, according to Zacks. Three analysts have made estimates for Momenta Pharmaceuticals’ earnings, with estimates ranging from ($0.55) to ($0.38). Momenta Pharmaceuticals posted earnings of ($0.63) per share in the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The business is expected to report its next earnings report before the market opens on Thursday, May 2nd.

According to Zacks, analysts expect that Momenta Pharmaceuticals will report full year earnings of ($1.72) per share for the current fiscal year, with EPS estimates ranging from ($2.10) to ($1.24). For the next year, analysts expect that the firm will report earnings of ($1.72) per share, with EPS estimates ranging from ($2.16) to ($0.89). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Momenta Pharmaceuticals.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Friday, February 22nd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.39. The firm had revenue of $42.80 million during the quarter, compared to analysts’ expectations of $17.11 million. Momenta Pharmaceuticals had a negative net margin of 232.92% and a negative return on equity of 47.74%. The company’s quarterly revenue was down 33.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.18 EPS.



Several brokerages have recently commented on MNTA. Cantor Fitzgerald reiterated a “hold” rating and set a $16.00 price target on shares of Momenta Pharmaceuticals in a research report on Friday, February 22nd. Stifel Nicolaus reiterated a “buy” rating and set a $29.00 price target on shares of Momenta Pharmaceuticals in a research report on Friday, February 22nd. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating and set a $16.00 price target for the company in a research report on Monday, February 25th. BTIG Research began coverage on shares of Momenta Pharmaceuticals in a research report on Monday, March 18th. They set a “neutral” rating and a $14.15 price target for the company. Finally, BidaskClub upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $22.03.

In other news, Director Bruce Downey sold 13,000 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $14.51, for a total transaction of $188,630.00. Following the completion of the sale, the director now owns 41,234 shares in the company, valued at approximately $598,305.34. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Craig A. Wheeler sold 2,601 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Friday, February 8th. The stock was sold at an average price of $11.76, for a total transaction of $30,587.76. Following the sale, the chief executive officer now owns 186,174 shares of the company’s stock, valued at approximately $2,189,406.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 96,393 shares of company stock valued at $1,342,719. 3.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in MNTA. FMR LLC boosted its stake in Momenta Pharmaceuticals by 25.7% during the 4th quarter. FMR LLC now owns 14,770,728 shares of the biotechnology company’s stock worth $163,069,000 after acquiring an additional 3,023,513 shares during the last quarter. Perceptive Advisors LLC boosted its stake in Momenta Pharmaceuticals by 11,435.8% during the 4th quarter. Perceptive Advisors LLC now owns 2,825,000 shares of the biotechnology company’s stock worth $31,132,000 after acquiring an additional 2,800,511 shares during the last quarter. Norges Bank bought a new position in Momenta Pharmaceuticals during the 4th quarter worth approximately $19,673,000. BlackRock Inc. boosted its stake in Momenta Pharmaceuticals by 14.0% during the 4th quarter. BlackRock Inc. now owns 13,775,141 shares of the biotechnology company’s stock worth $152,079,000 after acquiring an additional 1,694,797 shares during the last quarter. Finally, RA Capital Management LLC boosted its stake in Momenta Pharmaceuticals by 64.2% during the 4th quarter. RA Capital Management LLC now owns 2,558,357 shares of the biotechnology company’s stock worth $28,244,000 after acquiring an additional 1,000,000 shares during the last quarter. 96.85% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:MNTA traded up $0.25 during trading on Tuesday, hitting $14.70. 417,600 shares of the company’s stock were exchanged, compared to its average volume of 587,564. Momenta Pharmaceuticals has a 1-year low of $9.55 and a 1-year high of $32.20. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -7.31 and a beta of 2.23.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Recommended Story: Do stock splits help investors?

Get a free copy of the Zacks research report on Momenta Pharmaceuticals (MNTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.